Literature DB >> 6852546

The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale.

R D Venn.   

Abstract

In response to a need for an easily used general-purpose rating scale designed specifically for the evaluation of pharmacotherapy in senile dementia and related conditions, the Sandoz Clinical Assessment-Geriatric (SCAG) scale was developed. This scale has been widely used in geriatric psychopharmacologic research and has been found to be sensitive, valid, and reliable for this purpose. In order to provide investigators with guidelines for the evaluation of the 18 items and global evaluation provided on the scale, with a view to improving interrater reliability, a manual was developed for this purpose. As the existence of this manual is not widely known, it is presented so that the SCAG scale may be used in a more uniform manner from investigator to investigator.

Entities:  

Mesh:

Year:  1983        PMID: 6852546     DOI: 10.1159/000213113

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  6 in total

1.  Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data.

Authors:  K J Reinikainen; P J Riekkinen; L Paljärvi; H Soininen; E L Helkala; J Jolkkonen; M Laakso
Journal:  Neurochem Res       Date:  1988-02       Impact factor: 3.996

Review 2.  Drug treatment of Alzheimer's disease. Effects on caregiver burden and patient quality of life.

Authors:  L Hollister; N Gruber
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

Review 3.  Critical review of clinical trials in senile dementia--II.

Authors:  J M Orgogozo; R Spiegel
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

4.  Vitamin E and selenium supplementation in geriatric patients : A double-blind preliminary clinical trial.

Authors:  M Tolonen; M Halme; S Sarna
Journal:  Biol Trace Elem Res       Date:  1985-04       Impact factor: 3.738

5.  Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

Authors:  Philippe Robert; Steven Ferris; Serge Gauthier; Ralf Ihl; Bengt Winblad; Frank Tennigkeit
Journal:  Alzheimers Res Ther       Date:  2010-08-26       Impact factor: 6.982

6.  Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study.

Authors:  G Nappi; G Bono; P Merlo; A Borromei; C Caltagirone; C Lomeo; N Martucci; G Fabbrini; K Annoni; A Battaglia
Journal:  Clin Drug Investig       Date:  1997-06       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.